In the following video, Motley Fool health-care analyst David Williamson discusses Optimer's (NASDAQ: OPTR) 10% jump on word that the company will look into "strategic alternatives" in the midst of its current difficult times. David speculates that this means the company may be looking to sell, and he discusses who some potential buyers might be.
Optimer looks at some "strategic" moves.
David Williamson owns shares of Pfizer. The Motley Fool recommends Cubist Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.